Expert Analysis

Coverage of the 2005 Gastrointestinal Cancers Symposium

Source: CCO Independent Conference Coverage of the 2005 Gastrointestinal Cancers Symposium*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Coverage of the 2005 Gastrointestinal Cancers Symposium


Faculty:

Jim Cassidy, MB ChB, MSc, MD, FRCPJohn L. Marshall, MD
  • Jim Cassidy, MB ChB, MSc, MD, FRCP
  • John L. Marshall, MD

CME CREDIT INFORMATION

Release Date: 04/19/05

Expiration Date: 04/18/06


Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 2.1 Nursing CE credits

Pharmacists: 1.75 contact hours (0.18 CEUs)

Status: Please log in to view status

Begin the Expert Analysis

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare and contrast the benefits and disadvantages of neoadjuvant treatment approaches for a variety of GI malignancies.

  • Discuss the integration of targeted therapies in the treatment of GI malignancies.

  • Review the latest diagnostic and prognostic tools for managing GI malignancies.


Earn CME credit by reading summaries and expert commentary on the management of patients with gastrointestinal cancers.

Topics covered include:

  • Cisplatin- vs Irinotecan-Containing Combination Regimens in the Treatment of Gastric Cancer
  • Oxaliplatin Plus Infusional 5-Fluorouracil/Leucovorin or Capecitabine as First-line Treatment for Advanced Colorectal Carcinoma
  • Bortezomib-Containing Regimens for Gastric and Gastroesophageal Cancers
  • Treatment of Advanced Pancreatic Cancer With Erlotinib and Gemcitabine
  • Cetuximab/Bevacizumab for Irinotecan-refractory Colorectal Cancer
  • Prognostic Role of CA19-9 in Patients With Pancreatic Cancer
  • HER Dimerization and Prognosis in Metastatic Colorectal Cancer
  • Novel Targets for Chemoprevention of Gastric Cancer
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grant provided by:

Educational grants support only the CME-certified components of this program.